October 16, 2023 Background: Oncovita, a biotech company spin-off from Institut Pasteur, Paris, is developing a therapeutic vaccine in oncology based on Measovir®, a proprietary technology derived from the safe and highly immunogenic measles attenuated vaccine virus (MV). MV is a paramyxovirus with a negative strand RNA genome. The MV specific tropism for cancer
MVdeltaC shows encouraging results in several preclinical models of solid tumors such as mesothelioma, bladder cancer and neuroblastoma Paris, France, November 2, 2022 – Oncovita, a French biotech company specialized in therapeutic and prophylactic vaccines, today announces that the main preclinical data on MVdeltaC, its first therapeutic vaccine candidate
MVdeltaC, un nouveau vaccin thérapeutique démontre des activités immuno-oncolytiques précliniques prometteuses Frédéric Tangy, Aleksandr Barinov, Atousa Arbabian, Chantal Combredet, Claude Ruffié (IP), Valérie Najburg (IP), Nicolas Boisgerault (Inserm), Marc Grégoire (Inserm), Véronique Riebbels (Oncovita), Jean-François Le Bigot (Oncovita) La société
Oncovita, a biotech company dedicated to the development of life-saving new treatments, in particular anti-cancer therapies, announces today that it has entered into a licensing agreement with Institut Pasteur, granting it an exclusive worldwide license to develop, manufacture and commercialize therapies based on the immuno-oncolytic measles virus platform.
Specific advantages of Oncovita measles platform: Unique specificity for cancer cells due to CD46 measles vaccine receptor overexpression on most cancer cells, Strong capacity of MVdeltaC to induce danger signals and immunogenic cell death related to the presence of high amounts of RIG-I agonists, Demonstrated safety with a human track record that no other virus
Unleashing the patient’s own power to fight cancer with a safe and effective vaccine
Oncovita is the owner of a highly disruptive virus vector technology, the Measovir (TM) platform, to produce new oncovirotherapies
Cancer is the second leading cause of death in the Western world. By 2030, the global burden is expected to grow to 21 million new cases and 13 million deaths